The FDA voted to add this popular peptide to its compounding list. Here’s what to know

By MDLinx staffFact-checked by Davi ShermanPublished August 3, 2026

Industry Buzz

The intent here is to give some form of legitimacy by allowing those on the board who coincidentally own peptide clinics to say that this is FDA approved. It’s a slippery slope, where they slowly push these things into legitimacy.

—Physician via Reddit @NotShipNotShape

The FDA’s Pharmacy Compounding Advisory Committee has taken a step that would have been difficult to imagine just a few years ago: Recommending that several high-profile peptides (including the social-media favorite BPC-157) be added to the 503A compounding bulks list, potentially allowing compounding pharmacies to prepare them for prescription use.^[]^[]

The recommendation is nonbinding, and the FDA will ultimately decide whether to move forward.

The proposal raises concerns about whether substances with little high-quality human evidence for safety or efficacy belong on this regulatory pathway.

A different path than traditional drug approval

BPC-157 has become enormously popular in longevity, sports medicine, and wellness circles. Online, it’s promoted for everything from tissue healing to gut repair, despite a striking lack of robust clinical evidence.^[]

Rather than evaluating the peptide through the traditional FDA drug approval process, the committee was asked to vote on whether it belongs on the list of bulk drug substances that may be used by compounding pharmacies.^[]

Adding a substance to the compounding list is not equivalent to FDA approval, but critics worry many patients may not appreciate that difference.

I hope [in] two years all these people will be gone and all these decisions revisited. May need to spend 4 years just assessing all the damage.

—OB/GYN via Reddit @Deep_Stick8786

FDA scientists recommended ‘no’

FDA staff scientists recommended against adding each of the peptides under review. Their concern was that the evidence simply wasn’t there.^[]

According to FDA briefing documents discussed during the hearing, available studies were limited, frequently preclinical, and often too small or methodologically weak to support conclusions about clinical benefit.

Existing FDA-approved therapies already exist for many of the proposed indications. Supporters have pointed to the possible role of semax in cerebral ischemia, but the available stroke literature is extremely limited, relying largely on two publications from the same Russian research group.

Meanwhile, acute ischemic stroke already has multiple evidence-based interventions supported by extensive clinical trials and guideline recommendations.^[]

“There are also FDA-approved interventions for stroke … a medical emergency, and for all others, including insomnia, narcolepsy, and headaches,” wrote @ddx-me, an MD, on Reddit.

The conflict-of-interest question

The meeting also reignited debate over advisory committee composition. It’s reported that several recently appointed voting members could benefit financially if compounded peptides become more widely available.^[]

“A lot of people are going to get very rich from these decisions. At the cost of their morals,” wrote pharmacist @XmasTwinFallsIdaho on Reddit.

Conflicts of interest do not automatically invalidate scientific opinions. However, when evidence is sparse, transparency becomes especially important because subjective judgment inevitably carries greater weight.

“The intent here is to give some form of legitimacy by allowing those on the board who coincidentally own peptide clinics to say that this is FDA approved. It’s a slippery slope, where they slowly push these things into legitimacy. … If the specific peptides approved are actually proven to be evidence based, that’s great for them. If the specific peptides approved are proven to not work? They don’t care, because they’ll have made their money,” wrote @NotShipNotShape, an MD, on Reddit.

Is allowing compounding actually safer?

Patients are already buying peptides. If legitimate compounding pharmacies can produce standardized products under physician supervision, perhaps patients will move away from unregulated online vendors.

Opponents countered that compounding was never intended as a substitute for generating clinical evidence.^[]

They warned that expanding access before demonstrating benefit could reduce incentives for manufacturers to go through the FDA’s rigorous drug approval process while potentially giving patients an exaggerated sense of legitimacy.^[]

What should physicians tell patients?

Interest in peptides isn’t likely to disappear regardless of the FDA’s eventual decision. That means clinicians should be prepared for conversations with patients who assume BPC-157 or similar compounds are “FDA-approved” because they’re available through a prescription.

Helpful counseling points include:

Compounded does not mean FDA-approved.
Most marketed claims for BPC-157 remain unsupported by large, randomized human trials.
Animal data frequently fail to translate into clinical benefit.
Unknown long-term safety remains a major concern because systematic human studies are lacking.
Patients purchasing peptides online face additional risks related to purity, contamination, dosing consistency, and product authenticity.

The bigger question

This debate extends far beyond BPC-157. Historically, compounds became widely prescribed after demonstrating safety and efficacy through increasingly rigorous clinical trials. When it comes to peptides, though, widespread consumer demand has led to these regulatory discussions, even without robust evidence.

Whether that represents sensible harm reduction or an erosion of evidence-based standards depends largely on one’s view of the FDA’s role.

If the agency ultimately follows the committee’s recommendation, physicians may soon find themselves explaining an uncomfortable nuance to patients: A medication can be legally compounded and prescribed without ever having demonstrated the level of evidence typically expected for FDA-approved drugs.

For clinicians committed to evidence-based practice, that distinction may become the most important takeaway of all.

SHARE THIS ARTICLE